Research programme: neurological disorder therapeutics - Healx
Latest Information Update: 28 Dec 2023
At a glance
- Originator Healx
- Developer FRAXA Research Foundation; Healx
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Early infantile epileptic encephalopathy 2; Fragile X syndrome; Pitt-Hopkins syndrome
Highest Development Phases
- No development reported Early infantile epileptic encephalopathy 2; Fragile X syndrome; Pitt-Hopkins syndrome
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Early-infantile-epileptic-encephalopathy-2 in United Kingdom
- 28 Dec 2023 No recent reports of development identified for preclinical development in Fragile-X-syndrome in United Kingdom
- 28 Dec 2023 No recent reports of development identified for preclinical development in Pitt-Hopkins-syndrome in United Kingdom